Check out these blog posts from our Scientific Advisory Board members and other partners from the scientific community explaining the latest RET research.
RET Research News and Information
RET Cancer Research Takes Center Stage at ASCO, May 2026
RET Cancer Research Takes Center Stage at ASCO, May 2026
Don’t Miss Together Separately, presented by LCRF and the Susan Wojcicki Foundation on May 14th, 2026
Don’t Miss Together Separately, presented by LCRF and the Susan Wojcicki Foundation on May 14th, 2026
BioNTech’s BNT116 mRNA cancer vaccine trial has opened a new RET cohort
BioNTech’s BNT116 mRNA cancer vaccine trial has opened a new RET cohort
Pralsetinib (GAVRETO) for RET+ Lung Cancer: Final ARROW Trial Results
Pralsetinib (GAVRETO) for RET+ Lung Cancer: Final ARROW Trial Results
New Global Findings from the RETgistry: Advancing Care for RET-Altered Cancers
New Global Findings from the RETgistry: Advancing Care for RET-Altered Cancers
The Future of RET Therapy for NSCLC (2026 TTLC Meeting)
The Future of RET Therapy for NSCLC (2026 TTLC Meeting)
Q&A from the 2025 RET Lung Cancer Annual Webinar
Q&A from the 2025 RET Lung Cancer Annual Webinar
2025 RET Cancer Research Update
2025 RET Cancer Research Update
The Role of Biomarker Testing in Early-Stage NSCLC: Why It’s Not Just for Advanced Disease
The Role of Biomarker Testing in Early-Stage NSCLC: Why It’s Not Just for Advanced Disease
2025 RET Webinar: Meet Our Speakers
2025 RET Webinar: Meet Our Speakers
Join the POISE study at Massachusetts General Hospital
Join the POISE study at Massachusetts General Hospital
RET Studies Presented at the IASLC 2025 World Conference on Lung Cancer
RET Studies Presented at the IASLC 2025 World Conference on Lung Cancer
Announcing the Lung Cancer Genetics Study Database
Announcing the Lung Cancer Genetics Study Database
Ellipses’ RET inhibitor EP0031 advances to Phase 2 clinical trials
Ellipses’ RET inhibitor EP0031 advances to Phase 2 clinical trials
RET Highlights Presented at the 2025 American Society of Clinical Oncology (ASCO)
